<DOC>
	<DOCNO>NCT00087633</DOCNO>
	<brief_summary>This 2-arm study design evaluate efficacy , safety , tolerability prophylactic PEGASYS plus COPEGUS liver transplantation hepatitis C , compare initiation antiviral therapy time clinical recurrence hepatitis C infection . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>PHOENIX Study - A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) COPEGUS ( Ribavirin ) Administered After Liver Transplantation Hepatitis C .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient least 18 year age Positive hepatitis C virus RNA pretransplantation Primary , singleorgan recipient ( cadaveric donor ) Liver transplant 10 16 week treatment initiation Multiorgan retransplant recipient Evidence current hepatitis B infection Seropositive human immunodeficiency ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>